| AACR Project GENIE: 100,000 cases and beyond TJ Pugh, JL Bell, JP Bruce, GJ Doherty, M Galvin, MF Green, ... Cancer Discovery 12 (9), 2044-2057, 2022 | 42 | 2022 |
| Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy S Kaczanowska, T Murty, A Alimadadi, CF Contreras, C Duault, ... Cancer Cell 42 (1), 35-51. e8, 2024 | 8 | 2024 |
| Genomic analysis of early-stage lung cancer reveals a role for TP53 mutations in distant metastasis D Van Egeren, K Kohli, JL Warner, PL Bedard, G Riely, E Lepisto, ... Scientific Reports 12 (1), 19055, 2022 | 4 | 2022 |
| Automated detection of the above anvil cirrus plume severe storm signature with deep learning C Liles, K Bedka, E Xia, YX Huang, R Biswas, C Dolan, AH Jafari, T Smith 2020 AMS Annual Meeting, 2020 | 3 | 2020 |
| Objective assessment of pitch accuracy in equal-tempered vocal music using signal processing approaches R Biswas, YVS Murthy, SG Koolagudi, SG Vishnu Smart Computing Paradigms: New Progresses and Challenges: Proceedings of …, 2020 | 3 | 2020 |
| Abstract CT142: GD2. Ox40. CD28. z CAR T cell trial in neuroblastoma and osteosarcoma S Ramakrishna, S Kaczanowska, T Murty, CF Contreras, M Merchant, ... Cancer Research 82 (12_Supplement), CT142-CT142, 2022 | 1 | 2022 |
| Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial ER Parra, J Zhang, DY Duose, E Gonzalez-Kozlova, MW Redman, ... Clinical Cancer Research, OF1-OF14, 2024 | | 2024 |
| Multi-omics analysis reveals immune features associated with immunotherapy benefit in squamous cell lung cancer patients from Phase III Lung-MAP S1400I trial. ER Parra, J Zhang, DY Duose, E Gonzalez-Kozlova, MW Redman, ... Clinical Cancer Research: an Official Journal of the American Association …, 2024 | | 2024 |
| Immune determinants of CAR-T expansion in solid tumor patients receiving GD2 CAR-T cell therapy T Murty, S Kaczanowska, A Alimadadi, C Contreras, C Duault, ... Cancer Research 83 (7_Supplement), 2142-2142, 2023 | | 2023 |
| Infiltration and spatial distribution of immune cells are associated clinical benefit from Nivolumab and Ipilimumab for previously treated patients with stage IV squamous cell … ER Parra, J Zhang, M Redman, R Lazcano, P Mario, CL Fernandez, ... Cancer Research 82 (12_Supplement), 2580-2580, 2022 | | 2022 |
| Dynamic changes in circulating protein levels reveal an association between ipilimumab and nivolumab combination treatment (SWOG Lung-MAP S1400I trial) with outcomes in … E Gonzalez-Kozlova, HH Huang, M Redman, R Herbst, S Gettinger, ... Cancer Research 82 (12_Supplement), 5026-5026, 2022 | | 2022 |
| Immune gene expression signatures associated clinical benefit from nivolumab and ipilimumab for previously treated patients with stage IV squamous cell lung cancer: An immune … DY Duose, J Zhang, M Redman, B Zhang, E Cerami, J Lindsay, J Yu, ... Cancer Research 82 (12_Supplement), 1974-1974, 2022 | | 2022 |
| Dynamic changes in serum analyte levels associated with clinical outcome in squamous cell lung cancer trial SWOG Lung-MAP S1400I of nivolumab±ipilimumab. E Gonzalez-Kozlova, HH Huang, MW Redman, RS Herbst, SN Gettinger, ... Journal of Clinical Oncology 40 (16_suppl), 9044-9044, 2022 | | 2022 |
James LindsayAssociate Director of Knowledge Systems Group, Dana-Farber Cancer InstituteVerified email at dfci.harvard.edu
